Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company

Next Previous
Drug Profile

Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company

Alternative Names: DB103; LY 2140023; LY 2812223; LY 404039 prodrug; LY2140023 monohydrate; mGlu 2/3; mGlu2/3 pro II

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Denovo Biopharma; Eli Lilly and Company; National Institute of Drug Abuse; New York University School of Medicine; University of California at Los Angeles
  • Class Amides; Antipsychotics; Carboxylic acids; Drug withdrawal therapies; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Schizophrenia; Substance-related disorders
  • Discontinued Post-traumatic stress disorders

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Schizophrenia in USA (PO, Tablet)
  • 14 Dec 2021 Pomaglumetad methionil is still in clinical development for schizophrenia in USA
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Substance-related disorders in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top